Drug Research
Introducing ReciPredict: Revolutionising Drug Product Development and Manufacturing
Recipharm announced the launch of ReciPredict, a cutting-edge platform for Quality by Design (QbD), designed to transform the landscape of drug product development, tech transfer and manufacturing. With its innovative combination and systematic application of material sciences, statistical tools...
Drug Research
Radiopharmaceuticals : Rapid Growth And Rising Investments
The radiopharmaceutical industry is growing very quickly. In the past few years, there have been more mergers and acquisitions (M&A) and partnerships. Investors can find good business chances by learning more about this field.
Recent mergers, purchases, and joint deals...
Drug Research
GSKs Lung Cancer ADC Earns FDA Breakthrough Designation
The FDA has granted breakthrough status to an antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion agreement last year.
The pharma firm said that GSK5764227 (GSK'227, formerly known as HS-20093) has been granted the...
Drug Research
Bayer And NextRNA Partner On New Small Molecule Cancer Drugs
Bayer and NextRNA Therapeutics, a biotechnology company, announced that they would be working together to create a new type of small molecule cancer drug. The two companies agreed to a deal that could be worth over $500 million.
The two...
Drug Research
Strategies To Improve Cell Line Development For Biologics
The capacity of a cell line to create a biologic that is both safe and stable in large numbers may be considerably improved by the use of a variety of procedures by those who develop pharmaceuticals. On the other...
Drug Research
Nuclear Medicine In North America: Market Growth & Trends
The North American nuclear medicine market was estimated to be worth USD 2.05 billion in 2023 and is expected to develop rapidly over the next few years, with a compound annual growth rate (CAGR) of 9.90% through 2029.
Within the...
Drug Research
Bayer & NextRNA Partner In $547Million Cancer Therapy Deal
This summer, Bayer officials made sure Fierce understood that the company's desire for deals hasn't been stifled by a group-wide reorganization. Its most recent partnership aimed at treating cancer indicates that Bayer has, in fact, not lost interest in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.